



COUNTY OF LOS ANGELES
Public Health

JONATHAN E. FIELDING, M.D., M.P.H.
Director and Health Officer

JONATHAN E. FREEDMAN
Acting Chief Deputy

Alcohol and Drug Program Administration

WAYNE K. SUGITA, M.P.A.
Acting Director
1000 South Fremont Avenue
Building A-9 East, Third Floor
Alhambra, CA 91803
TEL (626) 299-4193 • FAX (626) 458-7637

www.publichealth.lacounty.gov

June 16, 2008



BOARD OF SUPERVISORS

Gloria Molina
First District
Yvonne B. Burke
Second District
Zev Yaroslavsky
Third District
Don Knabe
Fourth District
Michael D. Antonovich
Fifth District

TO: Each Health Deputy
FROM: *Wayne K. Sugita* Wayne K. Sugita, M.P.A., Acting Director
Alcohol and Drug Program Administration
SUBJECT: **FUNDING AUGMENTATION FOR THE PAJO CORPORATION,
CONTRACT NO. H-701122**

This is to inform you that we plan to amend the County estimated maximum obligation and corresponding maximum allocation for The Pajo Corporation using the delegated authority granted by the Board on May 31, 2005 (Board Agenda Synopsis #42). This agency's agreement provides flexibility to adjust funding allocations, and contains provisions that authorize the Director of Public Health or his designee to make such funding changes.

I am recommending this funding increase based on the Sobky v. Smoley court litigation which allowed agencies to request additional funds to cover persons eligible for Drug/Medi-Cal services. The current and proposed funding amounts are as indicated in the following attachments:

Attachment 1 - Description of the services affected by this amendment
Attachment 2 - Agency's current and proposed funding amounts

If you have any questions or need additional information, please let me know.

WKS:fg

Attachments

c: Jonathan E. Fielding, M.D., M.P.H.
Richard Martinez
Tami Omoto-Frias
Paul H.S. Kim
Jonathan E. Freedman
Wendy Schwartz

Drug/Medi-Cal Services - Description

Narcotic Treatment Program Services (Federal Drug/Medi-Cal)

Narcotic treatment program services provide for the administration of methadone and/or levoalphacetylmethadol, at relatively stable dosage levels for a period in excess of 21 days, as an oral substitute narcotic drug accompanied by ancillary social and medical services for individuals 18 years or older who have a history of two or more years of dependence on heroin or other morphine-like drugs, and two or more failures in alternative treatment programs. Services are provided to Medi-Cal eligible beneficiaries.

THE PAJO CORPORATION FUNDING INFORMATION

(Revised)

ATTACHMENT 2

<u>Contract #</u>	<u>Fac #</u>	<u>Site Address</u>	<u>SPA</u>	<u>SUP</u>	<u>Modality Desc</u>	<u>Modality</u>	<u>Original Board-Approved Amount</u>	<u>Current Funding Allocation FY 2007-08</u>	<u>Proposed Funding Allocation FY 2007-08</u>	<u>Total Funding Allocation FY 2007-08</u>
H-701122A	1	2080 Century Park East, Suite 1802 Century City CA 90067	5	3	Narcotic Treatment Program Services (Federal Drug/Medi-Cal)	NTP (DMC)	\$545,120	\$545,120	\$725,120	\$180,000
H-701122A	2	11900 Avalon Boulevard, Suite 200 Los Angeles CA 90061	6	2	Narcotic Treatment Program Services (Federal Drug/Medi-Cal)	NTP (DMC)				
							<hr/>	<hr/>	<hr/>	<hr/>
							\$545,120	\$545,120	\$725,120	\$180,000